MIMEDX Announces $25 Million Patent License Agreement

MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into a license agreement with a wound care competitor that resolves allegations of infringement of MIMEDX’s patents.

Under the terms of the agreement: * The licensee will pay MIMEDX a total of $25 million in five equal installments of $5 million. * The first installment has been received, and the four remaining installments will be paid annually on the anniversary of the signing date. * MIMEDX has granted the licensee a non-exclusive license to the covered patents. “This agreement underscores the strength and value of the intellectual property portfolio MIMEDX has built since its inception. We believe our expertise in placental biologics is unmatched, and this agreement recognizes the innovation behind our product portfolio and pipeline. It also provides MIMEDX with meaningful, recurring cash over the next several years. We will continue to vigorously protect our intellectual property while investing in further innovation and differentiation in the marketplace,” said Joseph H. Capper, Chief Executive Officer of MIMEDX.